Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia’s PBS Lists Four Adalimumab Biosimilars

‘A-Flag’ Allows Substitution For Humira As Well As Between Biosimilars

Executive Summary

Four different biosimilar versions of Humira will be listed on Australia’s PBS from the start of April, with the country’s “a-flagging” mechanism allowing substitution for the brand and between adalimumab biosimilars.

You may also be interested in...



Pfizer Bids To Stop Samsung Bioepis’ Etanercept In Australia

Enbrel (etanercept) originator Pfizer has filed suit in Australia over the sale of Samsung Bioepis’ rival Brenzys biosimilar. It alleges that it has “suffered, and will continue to suffer, substantial loss and damage.”

Organon Outlines Importance Of Speed For US Humira Opportunity

At its debut year-end financial earnings call, Organon spoke in further detail about the impending launch of Humira biosimilars, as well as its desire to continue growing its portfolio.

Australian Association Alleges Anti-Competitive Adalimumab Antics From AbbVie

AbbVie is spreading confusion among Australian doctors and patients with anti-competitive materials designed to fend off biosimilar adalimumab competition to Humira, according to a local biosimilars industry association.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel